Clinical trial Recruiting at 1 site Observational Ages 15 and up

ERCP (endoscopic retrograde cholangiopancreatography) procedure registry at Methodist Dallas Medical Center

Official title: Endoscopic Retrograde Cholangiopancreatography Patient Registry

Run by Methodist Health System · NCT07490132 · Data updated 2026-11-12

This registry collects information on ERCP procedures to see which patient and procedure factors affect post-ERCP pancreatitis for people over 15 who had ERCP at Methodist Dallas.

Quick facts

Study typeObservational
Ages15 Years and up
SexAll
Enrollment100 (estimated)
SponsorMethodist Health System
Academic / other
Locations1 site (Dallas, Texas)
StatusRecruiting
StartedFebruary 2026
Main results expectedFebruary 2027
Study endsFebruary 2028
Registry record updatedMarch 24, 2026
Trial IDNCT07490132 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

People older than 15 who underwent ERCP at Methodist Dallas Medical Center between January 1, 2000 and December 31, 2025 and are included in the MDI registry are eligible.

Probably not a fit

Patients under 15, those with cannulation via a surgical anastomosis, or those in whom cannulation was not attempted due to gastric outlet obstruction or an unidentifiable papilla are not included and therefore will not benefit from this registry.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center registry will collect detailed clinical and procedural information for patients older than 15 who underwent ERCP at Methodist Dallas Medical Center between January 1, 2000 and December 31, 2025. Data elements will include patient risk factors, procedural techniques, and outcomes including occurrence of post-ERCP pancreatitis. Patients whose cannulation was via a surgical anastomosis or in whom cannulation was not attempted due to gastric outlet obstruction or an unidentifiable papilla are excluded. The registry is intended to support quality improvement efforts and future research on strategies to reduce post-ERCP pancreatitis.

Why it matters

Potential benefit: If successful, the registry could identify modifiable risk factors and procedural practices that reduce the rate of post-ERCP pancreatitis and improve patient safety.

How similar studies have gone: Similar single-center and multicenter ERCP registries and targeted interventions (for example pancreatic stents and rectal NSAIDs) have identified risk factors and helped reduce post-ERCP pancreatitis in other settings, so the registry approach is established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Patients \>15 years Included in MDI's Registry Underwent ERCP between January 1, 2000 through December 31, 2025

Exclusion Criteria:

Patients \<15 years Patients in which cannulation was via a surgical anastomosis Patients in which cannulation was not attempted due to gastric outlet obstruction, the main papilla not found, or the minor papilla was not found will be excluded.

Where it's running

  • Methodist Dallas Medical Center- Clinical Research Institute
    Dallas, Texas, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.